Singapore Institute of Advanced Medicine Holdings Pte Ltd (SAM) and ProNova announced that ProNova has been selected by SAM as its partner to establish the first proton therapy facility in Singapore.  The SC360 proton therapy system will be an essential element of a new outpatient cancer center located on the Singapore Biopolis campus, an international research and development center for biomedical sciences.

ProNova will equip the new centre with two superconducting gantry proton treatment rooms including an additional room dedicated to research.  Each treatment room will include Fast Scanning IMPT technology with integrated 3D imaging.  This unique solution merges leading edge pencil beam delivery with innovative imaging capability to aid physicians and therapists in minimising collateral damage to healthy tissue and maximising dose to the tumour.

“We believe proton therapy is a significant step forward in our treatment of cancer and ProNova has proven to be the best partner with next generation technology,” said Dr. Djeng Shih Kien, SAM’s founder and chairman.

“We are pleased to partner with SAM in bringing the first proton center to Singapore,” said Dr. Terry Douglass, chairman and chief executive officer, of ProNova Solutions. “We look forward to providing our unique total solutions offerings and sharing our proton therapy knowledge and clinical experience with SAM’s staff. We believe that the new developments in proton therapy and other cancer treatment technologies accomplished at the SAM ProNova Biopolis Cancer Center will be a major step in redefining the future of cancer treatment.”

The new $100 million cancer and proton center will be located on the Biopolis Campus in Singapore.  Biopolis is the hallmark of Singapore's R&D success. Today, leading pharmaceutical companies such as Abbott, GlaxoSmithKline, Lilly, Novartis, Schering-Plough and Takeda have established their R&D base in the Biopolis. There are now more than 2,000 scientists from around the world carrying out research on this campus.

The Singapore Biopolis is strategically located next to the Kent Ridge Campus, where a public hospital and medical school are located, thereby facilitating translational and clinical research. The specialised research institutes at Kent Ridge include the Cancer Science Institute of Singapore. Leading companies such as AstraZeneca and Bayer Schering Pharma are partnering research units in the National University Health System at Kent Ridge for translational cancer research.